Rapport Therapeutics Clinical Trial Data
Rapport Therapeutics announced positive topline results from its Phase 2 trial of RAP-219 for the treatment of bipolar mania, meeting the primary endpoint with a statistically significant 3.1-point placebo-adjusted improvement in the YMRS total score. The drug was well-tolerated with no serious adverse events, establishing clinical proof-of-concept for its novel TARP g8-selective mechanism. The company plans to progress RAP-219 into Phase 3 trials for bipolar mania in the second half of 2027.